RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Paz-Ares, L
- Spigel, DR
- Chen, Y
- Jove, M
- Rich, P
- Hayes, T
- Calderon, VG
- Caro, RB
- Mendivil, AN
- Dowlati, A
- Zhang, B
- Moore, Y
- Wang, T
- Kokhreidze, J
- Ponce, S
- Bunn, P
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Keywords
- liposomal irinotecan; small-cell lung cancer; RESILIENT
Campos de Estudio
Cita
Paz,L,Spigel,DR,Chen,Y,Jove,M,Juan,O,Rich,P,Hayes,T et al. RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting. STE 800, 230 PARK AVE, NEW YORK, NY 10169:ELSEVIER SCIENCE INC. 2021 p.p. 505-505.
Portal de investigación